Regulatory T cells in the tumor microenvironment and cancer progression: Role and therapeutic targeting

Vaccines

Volumn 4, Issue 3, 2016, Pages

  Chaudhary, Belal ^a   Elkord, Eyad ^b,c,d,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF SALFORD   (United Kingdom)

Author keywords

Cancer progression; Regulatory T cells; Therapeutic targeting; Tumor microenvironment; Tumor infiltrating lymphocytes

Indexed keywords

BIOLOGY; CANCER GROWTH; CANCER THERAPY; HUMAN; IMMUNE RESPONSE; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 85016921823     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines4030028     Document Type: Review

References (172)

1. Sakaguchi, S.; Yamaguchi, T.; Nomura, T.; Ono, M. Regulatory T cells and immune tolerance. Cell 2008, 133, 775–787. [CrossRef] [PubMed]
2. Lee, H.M.; Bautista, J.L.; Hsieh, C.S. Thymic and peripheral differentiation of regulatory T cells. Adv. Immunol. 2011, 112, 25–71. [PubMed]
3. Yadav, M.; Stephan, S.; Bluestone, J.A. Peripherally induced tregs—Role in immune homeostasis and autoimmunity. Front. Immunol. 2013. [CrossRef] [PubMed]
4. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 2006, 212, 8–27. [CrossRef] [PubMed]
5. Weiner, H.L.; da Cunha, A.P.; Quintana, F.; Wu, H. Oral tolerance. Immunol. Rev. 2011, 241, 241–259. [CrossRef] [PubMed]
6. + T regulatory cell-mediated suppression. Immunity 2009, 30, 636–645. [CrossRef] [PubMed]
7. Schmidt, A.; Oberle, N.; Krammer, P.H. Molecular mechanisms of treg-mediated T cell suppression. Front. Immunol. 2012. [CrossRef] [PubMed]
8. + T cells expressing the FoxP3 transcription factor. Immunity 2009, 30, 899–911. [CrossRef] [PubMed]
9. + Treg cells that phenotypically mirror effector Th cells. Blood 2012, 119, 4430–4440. [CrossRef] [PubMed]
10. + regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood 2013, 122, 1802–1812. [CrossRef] [PubMed]
11. Mason, G.M.; Lowe, K.; Melchiotti, R.; Ellis, R.; de Rinaldis, E.; Peakman, M.; Heck, S.; Lombardi, G.; Tree, T.I. Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry. J. Immunol. 2015, 195, 2030–2037. [CrossRef] [PubMed]
12. Yamaguchi, T.; Wing, J.B.; Sakaguchi, S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin. Immunol. 2011, 23, 424–430. [CrossRef] [PubMed]
13. Vignali, D.A. Mechanisms of T(reg) Suppression: Still a LongWay to Go. Front. Immunol. 2012. [CrossRef] [PubMed]
14. Elkord, E.; Alcantar-Orozco, E.M.; Dovedi, S.J.; Tran, D.Q.; Hawkins, R.E.; Gilham, D.E. T regulatory cells in cancer: Recent advances and therapeutic potential. Expert Opin. Biol. Ther. 2010, 10, 1573–1586. [CrossRef] [PubMed]
15. Nishikawa, H.; Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 2014, 27, 1–7. [CrossRef] [PubMed]
16. Chaudhary, B.; Abd Al Samid, M.; al-Ramadi, B.K.; Elkord, E. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin. Biol. Ther. 2014, 14, 931–945. [CrossRef] [PubMed]
17. Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M.; et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942–949. [CrossRef] [PubMed]
18. Leffers, N.; Gooden, M.J.; de Jong, R.A.; Hoogeboom, B.N.; ten Hoor, K.A.; Hollema, H.; Boezen, H.M.; van der Zee, A.G.; Daemen, T.; Nijman, H.W. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 2009, 58, 449–459. [CrossRef] [PubMed]
19. + lymphocyte density in pancreatic cancer correlates with lymph node metastasis. PLoS ONE 2014, 9, e106741. [CrossRef] [PubMed]
20. Tang, Y.; Xu, X.; Guo, S.; Zhang, C.; Tang, Y.; Tian, Y.; Ni, B.; Lu, B.; Wang, H. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS ONE 2014, 9, e91551. [CrossRef] [PubMed]
21. Tao, H.; Mimura, Y.; Aoe, K.; Kobayashi, S.; Yamamoto, H.; Matsuda, E.; Okabe, K.; Matsumoto, T.; Sugi, K.; Ueoka, H. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 2012, 75, 95–101. [CrossRef] [PubMed]
22. + regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol. Immunother. 2015, 64, 419–427. [CrossRef] [PubMed]
23. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107, 3639–3646. [CrossRef] [PubMed]
24. + tumor-infiltrating lymphocytes in cancer: A critical review of the literature. Clin. Cancer Res. 2012, 18, 3022–3029. [CrossRef] [PubMed]
25. + regulatory T cells in cancers: A systematic review and meta-analysis. Sci. Rep. 2015. [CrossRef] [PubMed]
26. Rasku, M.A.; Clem, A.L.; Telang, S.; Taft, B.; Gettings, K.; Gragg, H.; Cramer, D.; Lear, S.C.; McMasters, K.M.; Miller, D.M.; et al. Transient T cell depletion causes regression of melanoma metastases. J. Transl. Med. 2008. [CrossRef] [PubMed]
27. + regulatory T cells. Clin. Cancer Res. 2008, 14, 2413–2420. [CrossRef] [PubMed]
28. Rech, A.J.; Mick, R.; Martin, S.; Recio, A.; Aqui, N.A.; Powell, D.J., Jr.; Colligon, T.A.; Trosko, J.A.; Leinbach, L.I.; Pletcher, C.H.; et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 2012. [CrossRef] [PubMed]
29. Haas, M.; Dimmler, A.; Hohenberger, W.; Grabenbauer, G.G.; Niedobitek, G.; Distel, L.V. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol. 2009. [CrossRef] [PubMed]
30. + T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009, 27, 186–192. [CrossRef] [PubMed]
31. + regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. Cancer Immunol. Immunother. 2011, 60, 909–918. [CrossRef] [PubMed]
32. Ondondo, B.; Jones, E.; Godkin, A.; Gallimore, A. Home sweet home: The tumor microenvironment as a haven for regulatory T cells. Front. Immunol. 2013. [CrossRef] [PubMed]
33. Kim, C.H. Reining in FoxP3(+) regulatory T cells by the sphingosine 1-phosphate-S1P1 axis. Immunol. Cell Biol. 2009, 87, 502–504. [CrossRef] [PubMed]
34. Priceman, S.J.; Shen, S.; Wang, L.; Deng, J.; Yue, C.; Kujawski, M.; Yu, H. S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3. Cell Rep. 2014, 6, 992–999. [CrossRef] [PubMed]
35. Fridman, W.H.; Pages, F.; Sautes-Fridman, C.; Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 2012, 12, 298–306. [CrossRef] [PubMed]
36. Giraldo, N.A.; Becht, E.; Remark, R.; Damotte, D.; Sautes-Fridman, C.; Fridman, W.H. The immune contexture of primary and metastatic human tumours. Curr. Opin. Immunol. 2014, 27, 8–15. [CrossRef] [PubMed]
37. Kakita, N.; Kanto, T.; Itose, I.; Kuroda, S.; Inoue, M.; Matsubara, T.; Higashitani, K.; Miyazaki, M.; Sakakibara, M.; Hiramatsu, N.; et al. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: A crucial role of CD25(‑)FOXP3(‑) T cells. Int. J. Cancer 2012, 131, 2573–2583. [CrossRef] [PubMed]
38. +FOXP3neg T-cell subsets in cancer patients. Eur. J. Immunol. 2012, 42, 1876–1885. [CrossRef] [PubMed]
39. Jie, H.B.; Gildener-Leapman, N.; Li, J.; Srivastava, R.M.; Gibson, S.P.; Whiteside, T.L.; Ferris, R.L. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br. J. Cancer 2013, 109, 2629–2635. [CrossRef] [PubMed]
40. Lin, Y.C.; Mahalingam, J.; Chiang, J.M.; Su, P.J.; Chu, Y.Y.; Lai, H.Y.; Fang, J.H.; Huang, C.T.; Chiu, C.T.; Lin, C.Y. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int. J. Cancer 2013, 132, 1341–1350. [CrossRef] [PubMed]
41. + regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. USA 2013, 110, 17945–17950. [CrossRef] [PubMed]
42. + regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013, 57, 183–194. [CrossRef] [PubMed]
43. Han, Y.; Yang, Y.; Chen, Z.; Jiang, Z.; Gu, Y.; Liu, Y.; Xu, S.; Lin, C.; Pan, Z.; Zhou, W.; et al. Human hepatocellular carcinoma-infiltrating CD4(+)CD69(+)Foxp3(-) regulatory T cell suppresses T cell response via membrane-bound TGF-beta1. J. Mol. Med. (Berl.) 2014, 92, 539–550. [CrossRef] [PubMed]
44. Scurr, M.; Ladell, K.; Besneux, M.; Christian, A.; Hockey, T.; Smart, K.; Bridgeman, H.; Hargest, R.; Phillips, S.; Davies, M.; et al. Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(‑) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells. Mucosal Immunol. 2014, 7, 428–439. [CrossRef] [PubMed]
45. Kurose, K.; Ohue, Y.; Sato, E.; Yamauchi, A.; Eikawa, S.; Isobe, M.; Nishio, Y.; Uenaka, A.; Oka, M.; Nakayama, E. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760). J. Thorac. Oncol. 2015, 10, 74–83. [CrossRef] [PubMed]
46. Amedei, A.; Niccolai, E.; Benagiano, M.; Della Bella, C.; Cianchi, F.; Bechi, P.; Taddei, A.; Bencini, L.; Farsi, M.; Cappello, P.; et al. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol. Immunother. 2013, 62, 1249–1260. [CrossRef] [PubMed]
47. Yi, Y.; He, H.W.; Wang, J.X.; Cai, X.Y.; Li, Y.W.; Zhou, J.; Cheng, Y.F.; Jin, J.J.; Fan, J.; Qiu, S.J. The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGFbetaand IL-10-dependent manner. J. Hepatol. 2013, 58, 977–983. [CrossRef] [PubMed]
48. Yuan, X.L.; Chen, L.; Li, M.X.; Dong, P.; Xue, J.; Wang, J.; Zhang, T.T.; Wang, X.A.; Zhang, F.M.; Ge, H.L.; et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin. Immunol. 2010, 134, 277–288. [CrossRef] [PubMed]
49. Yan, J.; Zhang, Y.; Zhang, J.P.; Liang, J.; Li, L.; Zheng, L. Tim-3 expression defines regulatory T cells in human tumors. PLoS ONE 2013, 8, e58006. [CrossRef] [PubMed]
50. Bu, M.; Shen, Y.; Seeger, W.L.; An, S.; Qi, R.; Sanderson, J.A.; Cai, Y. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression. Tumour Biol. 2016, 37, 3949–3956. [CrossRef] [PubMed]
51. Nirschl, C.J.; Drake, C.G. Molecular pathways: Coexpression of immune checkpoint molecules: Signaling pathways and implications for cancer immunotherapy. Clin. Cancer Res. 2013, 19, 4917–4924. [CrossRef] [PubMed]
52. Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am. J. Clin. Oncol. 2016, 39, 98–106. [CrossRef] [PubMed]
53. Rifkin, D.B. Latent transforming growth factor-beta (TGF-beta) binding proteins: Orchestrators of TGF-beta availability. J. Biol. Chem. 2005, 280, 7409–7412. [CrossRef] [PubMed]
54. + regulatory T cells. Proc. Natl. Acad. Sci. USA 2009, 106, 13445–13450. [CrossRef] [PubMed]
55. Sun, J.; Tang, D.N.; Fu, T.; Sharma, P. Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov. 2012, 2, 122–130. [CrossRef] [PubMed]
56. Mahalingam, J.; Lin, C.Y.; Chiang, J.M.; Su, P.J.; Chu, Y.Y.; Lai, H.Y.; Fang, J.H.; Huang, C.T.; Lin, Y.C. CD4(+) T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer. PLoS ONE 2014, 9, e108554. [CrossRef] [PubMed]
57. Abd Al Samid, M.; Chaudhary, B.; Khaled, Y.S.; Ammori, B.J.; Elkord, E. Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. Oncotarget 2016, 7, 14083–14094. [PubMed]
58. Whiteside, T.L. What are regulatory T cells (Treg) regulating in cancer and why? Semin. Cancer Biol. 2012, 22, 327–334. [CrossRef] [PubMed]
59. Sundstrom, P.; Stenstad, H.; Langenes, V.; Ahlmanner, F.; Theander, L.; Ndah, T.G.; Fredin, K.; Borjesson, L.; Gustavsson, B.; Bastid, J.; et al. Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cellMigration through an Adenosine-DependentMechanism. Cancer Immunol. Res. 2016, 4, 183–193. [CrossRef] [PubMed]
60. + cells. Clin. Exp. Immunol. 2014, 177, 531–543. [CrossRef] [PubMed]
61. Dunne, M.R.; Ryan, C.; Nolan, B.; Tosetto, M.; Geraghty, R.; Winter, D.C.; O’Connell, P.R.; Hyland, J.M.; Doherty, G.A.; Sheahan, K.; et al. Enrichment of Inflammatory IL-17 and TNF-alpha Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1. Front. Oncol. 2016. [CrossRef] [PubMed]
62. Deaglio, S.; Dwyer, K.M.; Gao, W.; Friedman, D.; Usheva, A.; Erat, A.; Chen, J.F.; Enjyoji, K.; Linden, J.; Oukka, M.; et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204, 1257–1265. [CrossRef] [PubMed]
63. + T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007, 13, 4345–4354. [CrossRef] [PubMed]
64. Saito, T.; Nishikawa, H.; Wada, H.; Nagano, Y.; Sugiyama, D.; Atarashi, K.; Maeda, Y.; Hamaguchi, M.; Ohkura, N.; Sato, E.; et al. Two FOXP3CD4 T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 2016, 22, 679–684. [CrossRef] [PubMed]
65. Mailloux, A.W.; Young, M.R. Regulatory T-cell trafficking: From thymic development to tumor-induced immune suppression. Crit. Rev. Immunol. 2010, 30, 435–447. [CrossRef] [PubMed]
66. + T cells in a dose-dependent fashion. Blood 2008, 112, 1175–1183. [CrossRef] [PubMed]
67. Ishida, T.; Joh, T.; Uike, N.; Yamamoto, K.; Utsunomiya, A.; Yoshida, S.; Saburi, Y.; Miyamoto, T.; Takemoto, S.; Suzushima, H.; et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J. Clin. Oncol. 2012, 30, 837–842. [CrossRef] [PubMed]
68. Ogura, M.; Ishida, T.; Hatake, K.; Taniwaki, M.; Ando, K.; Tobinai, K.; Fujimoto, K.; Yamamoto, K.; Miyamoto, T.; Uike, N.; et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J. Clin. Oncol. 2014, 32, 1157–1163. [CrossRef] [PubMed]
69. + CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clin. Cancer Res. 2015, 21, 4327–4336. [CrossRef] [PubMed]
70. Ni, X.; Jorgensen, J.L.; Goswami, M.; Challagundla, P.; Decker, W.K.; Kim, Y.H.; Duvic, M.A. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clin. Cancer Res. 2015, 21, 274–285. [CrossRef] [PubMed]
71. Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27, 5904–5912. [CrossRef] [PubMed]
72. Jiang, Y.; Li, Y.; Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell. Death Dis. 2015, 6, e1792. [CrossRef] [PubMed]
73. Lindau, D.; Gielen, P.; Kroesen, M.; Wesseling, P.; Adema, G.J. The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013, 138, 105–115. [CrossRef] [PubMed]
74. Pedroza-Pacheco, I.; Madrigal, A.; Saudemont, A. Interaction between natural killer cells and regulatory T cells: Perspectives for immunotherapy. Cell. Mol. Immunol. 2013, 10, 222–229. [CrossRef] [PubMed]
75. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005, 202, 1075–1085. [CrossRef] [PubMed]
76. Chang, W.C.; Li, C.H.; Chu, L.H.; Huang, P.S.; Sheu, B.C.; Huang, S.C. Regulatory T Cells Suppress Natural Killer Cell Immunity in PatientsWith Human Cervical Carcinoma. Int. J. Gynecol. Cancer 2016, 26, 156–162. [CrossRef] [PubMed]
77. Khaled, Y.S.; Ammori, B.J.; Elkord, E. Myeloid-derived suppressor cells in cancer: Recent progress and prospects. Immunol. Cell Biol. 2013, 91, 493–502. [CrossRef] [PubMed]
78. Dannenmann, S.R.; Thielicke, J.; Stockli, M.; Matter, C.; von Boehmer, L.; Cecconi, V.; Hermanns, T.; Hefermehl, L.; Schraml, P.; Moch, H.; et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013, 2, e23562. [CrossRef] [PubMed]
79. + regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl. Acad. Sci. USA 2007, 104, 19446–19451. [CrossRef] [PubMed]
80. Fujimura, T.; Kambayashi, Y.; Aiba, S. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 2012, 1, 1433–1434. [CrossRef] [PubMed]
81. Pyzer, A.R.; Cole, L.; Rosenblatt, J.; Avigan, D.E. Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Int. J. Cancer 2016. [CrossRef] [PubMed]
82. Maldonado, R.A.; von Andrian, U.H. How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 2010, 108, 111–165. [PubMed]
83. Pedroza-Gonzalez, A.; Zhou, G.; Vargas-Mendez, E.; Boor, P.P.; Mancham, S.; Verhoef, C.; Polak, W.G.; Grunhagen, D.; Pan, Q.; Janssen, H.; et al. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology 2015, 4, e1008355. [PubMed]
84. Burr, S.P.; Dazzi, F.; Garden, O.A. Mesenchymal stromal cells and regulatory T cells: The Yin and Yang of peripheral tolerance? Immunol. Cell Biol. 2013, 91, 12–18. [PubMed]
85. Taflin, C.; Favier, B.; Baudhuin, J.; Savenay, A.; Hemon, P.; Bensussan, A.; Charron, D.; Glotz, D.; Mooney, N. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc. Natl. Acad. Sci. USA 2011, 108, 2891–2896. [CrossRef] [PubMed]
86. Fu, H.; Kishore, M.; Gittens, B.; Wang, G.; Coe, D.; Komarowska, I.; Infante, E.; Ridley, A.J.; Cooper, D.; Perretti, M.; et al. Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation. Nat. Commun. 2014. [CrossRef] [PubMed]
87. Brinkman, C.C.; Iwami, D.; Hritzo, M.K.; Xiong, Y.; Ahmad, S.; Simon, T.; Hippen, K.L.; Blazar, B.R.; Bromberg, J.S. Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nat. Commun. 2016. [CrossRef] [PubMed]
88. +-inducible regulatory T cells suppress endothelial activation and leukocyte recruitment. J. Immunol. 2011, 187, 3521–3529. [CrossRef] [PubMed]
89. + lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol. Oncol. 2008, 110, 216–221. [CrossRef] [PubMed]
90. Facciabene, A.; Peng, X.; Hagemann, I.S.; Balint, K.; Barchetti, A.; Wang, L.P.; Gimotty, P.A.; Gilks, C.B.; Lal, P.; Zhang, L.; et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011, 475, 226–230. [CrossRef] [PubMed]
91. Muller, L.; Mitsuhashi, M.; Simms, P.; Gooding, W.E.; Whiteside, T.L. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci. Rep. 2016. [CrossRef] [PubMed]
92. Whiteside, T.L. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin. Biol. Ther. 2014, 14, 1411–1425. [CrossRef] [PubMed]
93. Zhou, X.; Tang, J.; Cao, H.; Fan, H.; Li, B. Tissue resident regulatory T cells: Novel therapeutic targets for human disease. Cell. Mol. Immunol. 2015, 12, 543–552. [CrossRef] [PubMed]
94. Trinchieri, G. Cancer and inflammation: An old intuitionwith rapidly evolving newconcepts. Annu. Rev. Immunol. 2012, 30, 677–706. [CrossRef] [PubMed]
95. Bremnes, R.M.; Al-Shibli, K.; Donnem, T.; Sirera, R.; Al-Saad, S.; Andersen, S.; Stenvold, H.; Camps, C.; Busund, L.T. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: Emphasis on non-small cell lung cancer. J. Thorac. Oncol. 2011, 6, 824–833. [CrossRef] [PubMed]
96. Smigiel, K.S.; Srivastava, S.; Stolley, J.M.; Campbell, D.J. Regulatory T-cell homeostasis: Steady-state maintenance and modulation during inflammation. Immunol. Rev. 2014, 259, 40–59. [CrossRef] [PubMed]
97. Erdman, S.E.; Rao, V.P.; Olipitz, W.; Taylor, C.L.; Jackson, E.A.; Levkovich, T.; Lee, C.W.; Horwitz, B.H.; Fox, J.G.; Ge, Z.; et al. Unifying roles for regulatory T cells and inflammation in cancer. Int. J. Cancer 2010, 126, 1651–1665. [CrossRef] [PubMed]
98. Bergmann, C.; Strauss, L.; Wang, Y.; Szczepanski, M.J.; Lang, S.; Johnson, J.T.; Whiteside, T.L. Tregulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 2008, 14, 3706–3715. [CrossRef] [PubMed]
99. Betts, G.; Jones, E.; Junaid, S.; El-Shanawany, T.; Scurr, M.; Mizen, P.; Kumar, M.; Jones, S.; Rees, B.; Williams, G.; et al. Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012, 61, 1163–1171. [CrossRef] [PubMed]
100. Gavin, M.A.; Torgerson, T.R.; Houston, E.; DeRoos, P.; Ho, W.Y.; Stray-Pedersen, A.; Ocheltree, E.L.; Greenberg, P.D.; Ochs, H.D.; Rudensky, A.Y. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 2006, 103, 6659–6664. [CrossRef] [PubMed]
101. +FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007, 110, 2983–2990. [CrossRef] [PubMed]
102. Santegoets, S.J.; Dijkgraaf, E.M.; Battaglia, A.; Beckhove, P.; Britten, C.M.; Gallimore, A.; Godkin, A.; Gouttefangeas, C.; de Gruijl, T.D.; Koenen, H.J.; et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol. Immunother. 2015, 64, 1271–1286. [CrossRef] [PubMed]
103. Adeegbe, D.O.; Nishikawa, H. Natural and induced T regulatory cells in cancer. Front. Immunol. 2013. [CrossRef] [PubMed]
104. Elkord, E.; Abd Al Samid, M.; Chaudhary, B. Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. Oncotarget 2015, 6, 20026–20036. [CrossRef] [PubMed]
105. Marshall, N.A.; Christie, L.E.; Munro, L.R.; Culligan, D.J.; Johnston, P.W.; Barker, R.N.; Vickers, M.A. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103, 1755–1762. [CrossRef] [PubMed]
106. Dobrzanski, M.J.; Rewers-Felkins, K.A.; Samad, K.A.; Quinlin, I.S.; Phillips, C.A.; Robinson, W.; Dobrzanski, D.J.; Wright, S.E. Immunotherapy with IL-10- and IFN-gamma-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: Observations in four cases of patients with ovarian cancer. Cancer Immunol. Immunother. 2012, 61, 839–854. [CrossRef] [PubMed]
107. Wing, J.B.; Sakaguchi, S. Multiple treg suppressive modules and their adaptability. Front. Immunol. 2012. [CrossRef] [PubMed]
108. + T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res. 2012, 72, 4351–4360. [CrossRef] [PubMed]
109. Savage, P.A.; Leventhal, D.S.; Malchow, S. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol. Rev. 2014, 259, 245–258. [CrossRef] [PubMed]
110. Lu, Y.C.; Robbins, P.F. Cancer immunotherapy targeting neoantigens. Semin. Immunol. 2016, 28, 22–27. [CrossRef] [PubMed]
111. Francois, V.; Ottaviani, S.; Renkvist, N.; Stockis, J.; Schuler, G.; Thielemans, K.; Colau, D.; Marchand, M.; Boon, T.; Lucas, S.; et al. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res. 2009, 69, 4335–4345. [CrossRef] [PubMed]
112. Fourcade, J.; Sun, Z.; Kudela, P.; Janjic, B.; Kirkwood, J.M.; El-Hafnawy, T.; Zarour, H.M. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J. Immunol. 2010, 184, 6709–6718. [CrossRef] [PubMed]
113. Horn, T.; Grab, J.; Schusdziarra, J.; Schmid, S.; Maurer, T.; Nawroth, R.; Wolf, P.; Pritsch, M.; Gschwend, J.E.; Kubler, H.R.; et al. Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches. Int. J. Cancer 2013, 133, 2145–2156. [CrossRef] [PubMed]
114. + T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg. Cancer Immunol. Res. 2013, 1, 303–308. [CrossRef] [PubMed]
115. Bindea, G.; Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Waldner, M.; Obenauf, A.C.; Angell, H.; Fredriksen, T.; Lafontaine, L.; Berger, A.; et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39, 782–795. [CrossRef] [PubMed]
116. Gobert, M.; Treilleux, I.; Bendriss-Vermare, N.; Bachelot, T.; Goddard-Leon, S.; Arfi, V.; Biota, C.; Doffin, A.C.; Durand, I.; Olive, D.; et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69, 2000–2009. [CrossRef] [PubMed]
117. Faget, J.; Biota, C.; Bachelot, T.; Gobert, M.; Treilleux, I.; Goutagny, N.; Durand, I.; Leon-Goddard, S.; Blay, J.Y.; Caux, C.; et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res. 2011, 71, 6143–6152. [CrossRef] [PubMed]
118. Darrasse-Jeze, G.; Podsypanina, K. How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. Front. Immunol. 2013. [CrossRef] [PubMed]
119. Halvorsen, E.C.; Mahmoud, S.M.; Bennewith, K.L. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev. 2014, 33, 1025–1041. [CrossRef] [PubMed]
120. Tan, W.; Zhang, W.; Strasner, A.; Grivennikov, S.; Cheng, J.Q.; Hoffman, R.M.; Karin, M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470, 548–553. [CrossRef] [PubMed]
121. Ye, Y.; Zhou, Z.; Gu, W.; Peng, F.; Li, J. Treg increases HepG2 cell growth by RANK-RANKL pathway. J. Immunother. Cancer 2014. [CrossRef]
122. Whiteside, T. The role of regulatory T cells in cancer immunology. Immunotargets Ther. 2015, 4, 159–171. [CrossRef] [PubMed]
123. Gajewski, T.F.; Schreiber, H.; Fu, Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14, 1014–1022. [CrossRef] [PubMed]
124. Pere, H.; Tanchot, C.; Bayry, J.; Terme, M.; Taieb, J.; Badoual, C.; Adotevi, O.; Merillon, N.; Marcheteau, E.; Quillien, V.R.; et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012, 1, 326–333. [CrossRef] [PubMed]
125. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34, 336–344. [CrossRef] [PubMed]
126. Lutsiak, M.E.; Semnani, R.T.; De Pascalis, R.; Kashmiri, S.V.; Schlom, J.; Sabzevari, H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105, 2862–2868. [CrossRef] [PubMed]
127. Walter, S.; Weinschenk, T.; Stenzl, A.; Zdrojowy, R.; Pluzanska, A.; Szczylik, C.; Staehler, M.; Brugger, W.; Dietrich, P.Y.; Mendrzyk, R.; et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, 18, 1254–1261. [CrossRef] [PubMed]
128. +) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012, 119, 5688–5696. [CrossRef] [PubMed]
129. Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.H.; Ariyan, C.E.; Gordon, R.A.; Reed, K.; et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369, 122–133. [CrossRef] [PubMed]
130. Topalian, S.L.; Sznol, M.; McDermott, D.F.; Kluger, H.M.; Carvajal, R.D.; Sharfman, W.H.; Brahmer, J.R.; Lawrence, D.P.; Atkins, M.B.; Powderly, J.D.; et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014, 32, 1020–1030. [CrossRef] [PubMed]
131. Postow, M.A.; Callahan, M.K.; Wolchok, J.D. Immune Checkpoint Blockade in Cancer Therapy. J. Clin. Oncol. 2015, 33, 1974–1982. [CrossRef] [PubMed]
132. Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 2015, 372, 311–319. [CrossRef] [PubMed]
133. Maker, A.V.; Attia, P.; Rosenberg, S.A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 2005, 175, 7746–7754. [CrossRef] [PubMed]
134. O’Mahony, D.; Morris, J.C.; Quinn, C.; Gao, W.; Wilson, W.H.; Gause, B.; Pittaluga, S.; Neelapu, S.; Brown, M.; Fleisher, T.A.; et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 2007, 13, 958–964. [CrossRef] [PubMed]
135. Menard, C.; Ghiringhelli, F.; Roux, S.; Chaput, N.; Mateus, C.; Grohmann, U.; Caillat-Zucman, S.; Zitvogel, L.; Robert, C. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: Surrogate marker of efficacy of tremelimumab? Clin. Cancer Res. 2008, 14, 5242–5249. [CrossRef] [PubMed]
136. Ribas, A.; Comin-Anduix, B.; Economou, J.S.; Donahue, T.R.; de la Rocha, P.; Morris, L.F.; Jalil, J.; Dissette, V.B.; Shintaku, I.P.; Glaspy, J.A.; et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res. 2009, 15, 390–399. [CrossRef] [PubMed]
137. Ralph, C.; Elkord, E.; Burt, D.J.; O’Dwyer, J.F.; Austin, E.B.; Stern, P.L.; Hawkins, R.E.; Thistlethwaite, F.C. Modulation of lymphocyte regulation for cancer therapy: A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin. Cancer Res. 2010, 16, 1662–1672. [CrossRef] [PubMed]
138. Khan, S.; Burt, D.J.; Ralph, C.; Thistlethwaite, F.C.; Hawkins, R.E.; Elkord, E. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin. Immunol. 2011, 138, 85–96. [CrossRef] [PubMed]
139. Weber, J.S.; Hamid, O.; Chasalow, S.D.; Wu, D.Y.; Parker, S.M.; Galbraith, S.; Gnjatic, S.; Berman, D. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J. Immunother. 2012, 35, 89–97. [CrossRef] [PubMed]
140. Tarhini, A.A.; Butterfield, L.H.; Shuai, Y.; Gooding, W.E.; Kalinski, P.; Kirkwood, J.M. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J. Immunother. 2012, 35, 702–710. [CrossRef] [PubMed]
141. Tarhini, A.A.; Edington, H.; Butterfield, L.H.; Lin, Y.; Shuai, Y.; Tawbi, H.; Sander, C.; Yin, Y.; Holtzman, M.; Johnson, J.; et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE 2014, 9, e87705. [CrossRef] [PubMed]
142. Smyth, M.J.; Ngiow, S.F.; Teng, M.W. Targeting regulatory T cells in tumor immunotherapy. Immunol. Cell Biol. 2014, 92, 473–474. [CrossRef] [PubMed]
143. Furness, A.J.; Vargas, F.A.; Peggs, K.S.; Quezada, S.A. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 2014, 35, 290–298. [CrossRef] [PubMed]
144. Jie, H.B.; Schuler, P.J.; Lee, S.C.; Srivastava, R.M.; Argiris, A.; Ferrone, S.; Whiteside, T.L.; Ferris, R.L. CTLA-4(+) Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res. 2015, 75, 2200–2210. [CrossRef] [PubMed]
145. Romano, E.; Kusio-Kobialka, M.; Foukas, P.G.; Baumgaertner, P.; Meyer, C.; Ballabeni, P.; Michielin, O.; Weide, B.; Romero, P.; Speiser, D.E. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl. Acad. Sci. USA 2015, 112, 6140–6145. [CrossRef] [PubMed]
146. Hou, T.Z.; Qureshi, O.S.; Wang, C.J.; Baker, J.; Young, S.P.; Walker, L.S.; Sansom, D.M. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. J. Immunol. 2015, 194, 2148–2159. [CrossRef] [PubMed]
147. Sarnaik, A.A.; Yu, B.; Yu, D.; Morelli, D.; Hall, M.; Bogle, D.; Yan, L.; Targan, S.; Solomon, J.; Nichol, G.; et al. Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patientswith resected high-risk stage IIIc/IVmelanoma. Clin. Cancer Res. 2011, 17, 896–906. [CrossRef] [PubMed]
148. Bjoern, J.; Juul Nitschke, N.; Zeeberg Iversen, T.; Schmidt, H.; Fode, K.; Svane, I.M. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology 2016, 5, e1100788. [CrossRef] [PubMed]
149. +ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl. Acad. Sci. USA 2008, 105, 14987–14992. [CrossRef] [PubMed]
150. + T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin. Cancer Res. 2016. [CrossRef] [PubMed]
151. + CD25(Hi) regulatory T cells. Int. Immunol. 2009, 21, 1065–1077. [CrossRef] [PubMed]
152. Wang, C.; Thudium, K.B.; Han, M.; Wang, X.T.; Huang, H.; Feingersh, D.; Garcia, C.; Wu, Y.; Kuhne, M.; Srinivasan, M.; et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2014, 2, 846–856. [CrossRef] [PubMed]
153. Weber, J.S.; Kudchadkar, R.R.; Yu, B.; Gallenstein, D.; Horak, C.E.; Inzunza, H.D.; Zhao, X.; Martinez, A.J.; Wang, W.; Gibney, G.; et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J. Clin. Oncol. 2013, 31, 4311–4318. [CrossRef] [PubMed]
154. Gibney, G.T.; Kudchadkar, R.R.; DeConti, R.C.; Thebeau, M.S.; Czupryn, M.P.; Tetteh, L.; Eysmans, C.; Richards, A.; Schell, M.J.; Fisher, K.J.; et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin. Cancer Res. 2015, 21, 712–720. [CrossRef] [PubMed]
155. Tsai, K.K.; Daud, A.I. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J. Hematol. Oncol. 2015. [CrossRef] [PubMed]
156. Bowyer, S.; Prithviraj, P.; Lorigan, P.; Larkin, J.; McArthur, G.; Atkinson, V.; Millward, M.; Khou, M.; Diem, S.; Ramanujam, S.; et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br. J. Cancer 2016, 114, 1084–1089. [CrossRef] [PubMed]
157. Lumniczky, K.; Safrany, G. The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences. Cancer Lett. 2015, 356, 114–125. [CrossRef] [PubMed]
158. Di Maggio, F.M.; Minafra, L.; Forte, G.I.; Cammarata, F.P.; Lio, D.; Messa, C.; Gilardi, M.C.; Bravata, V. Portrait of inflammatory response to ionizing radiation treatment. J. Inflamm. (Lond.) 2015. [CrossRef] [PubMed]
159. Persa, E.; Balogh, A.; Safrany, G.; Lumniczky, K. The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett. 2015, 368, 252–261. [CrossRef] [PubMed]
160. Battaglia, A.; Buzzonetti, A.; Martinelli, E.; Fanelli, M.; Petrillo, M.; Ferrandina, G.; Scambia, G.; Fattorossi, A. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, 1546–1553. [CrossRef] [PubMed]
161. Fadul, C.E.; Fisher, J.L.; Gui, J.; Hampton, T.H.; Cote, A.L.; Ernstoff, M.S. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol. 2011, 13, 393–400. [CrossRef] [PubMed]
162. Schuler, P.J.; Harasymczuk, M.; Schilling, B.; Saze, Z.; Strauss, L.; Lang, S.; Johnson, J.T.; Whiteside, T.L. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin. Cancer Res. 2013, 19, 6585–6596. [CrossRef] [PubMed]
163. Sekar, D.; Hahn, C.; Brune, B.; Roberts, E.; Weigert, A. Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity. Eur. J. Immunol. 2012, 42, 1585–1598. [CrossRef] [PubMed]
164. Postow, M.A.; Callahan, M.K.; Barker, C.A.; Yamada, Y.; Yuan, J.; Kitano, S.; Mu, Z.; Rasalan, T.; Adamow, M.; Ritter, E.; et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012, 366, 925–931. [CrossRef] [PubMed]
165. Golden, E.B.; Demaria, S.; Schiff, P.B.; Chachoua, A.; Formenti, S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 2013, 1, 365–372. [CrossRef] [PubMed]
166. Twyman-Saint Victor, C.; Rech, A.J.; Maity, A.; Rengan, R.; Pauken, K.E.; Stelekati, E.; Benci, J.L.; Xu, B.; Dada, H.; Odorizzi, P.M.; et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520, 373–377. [CrossRef] [PubMed]
167. Janik, J.E.; Morris, J.C.; O’Mahony, D.; Pittaluga, S.; Jaffe, E.S.; Redon, C.E.; Bonner, W.M.; Brechbiel, M.W.; Paik, C.H.; Whatley, M.; et al. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma. Proc. Natl. Acad. Sci. USA 2015, 112, 13045–13050. [CrossRef] [PubMed]
168. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56, 641–648. [CrossRef] [PubMed]
169. Ge, Y.; Domschke, C.; Stoiber, N.; Schott, S.; Heil, J.; Rom, J.; Blumenstein, M.; Thum, J.; Sohn, C.; Schneeweiss, A.; et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome. Cancer Immunol. Immunother. 2012, 61, 353–362. [CrossRef] [PubMed]
170. Cha, E.; Klinger, M.; Hou, Y.; Cummings, C.; Ribas, A.; Faham, M.; Fong, L. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 2014. [CrossRef] [PubMed]
171. + T cell response. Sci. Transl. Med. 2014. [CrossRef] [PubMed]
172. Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515, 568–571. [CrossRef] [PubMed]